Market by Type, Delivery Mode, Application, End-user, Sales Channel, and Country Outlook | Forecast 2022-2028
A study by Triton Market
Research on North America’s immunoglobulin market shows that it would develop
with a CAGR of 6.85% in the forecasted period of 2022-2028.
Report scope can be customized per your requirements. Request For Customization
The
countries studied in this market include:
• Canada
• The United States
The immunoglobulin market in
the region is advancing due to the pervasiveness of various immunodeficiency
diseases across the United States and Canada. The market in the region is
expected to see a boost in revenue due to the adoption of immunoglobulin
products in the region and the presence of prominent industry leaders. This
creates a scope of technological advancement and product development, further
enhancing market growth.
According to a report
published by the National Institutes of Health, the United States has around
50,000 people suffering from 200 different primary immunodeficiency diseases.
The increased incidence of these diseases promotes the demand for
immunoglobulin therapy. The increase in product approvals by the FDA and the
high prevalence of different diseases in the country are some factors that
accelerate the market growth in the country.
Whereas, in Canada,
intravenous immunoglobulin is licensed by Health Canada for treating primary
and secondary immunodeficiency diseases such as allogeneic bone marrow
transplantation, pediatric HIV
infection, Kawasaki disease etc. The prevalence of such diseases will give rise
to the immunoglobulin market in the forecasted period. Furthermore, the
development of infrastructure around plasma and immunoglobulin in recent years
is expected to strengthen the market growth.
The growing use of human
immunoglobulin in hospitals & clinics for treating a wide range of diseases
has significantly reduced the risk of life-threatening infections. Further, its
use has led to improvement in the growth of the geriatric population, thus
aiding in the overall quality of life. Besides, an increase in the number of
hospitals and clinics, growth in healthcare spending and hospital supplies, and
escalating inpatient days are boosting the demand for immunoglobulin by this end-user.
The
studied report evaluates the market based on type, delivery mode, application,
end-user, and sales channel. The end-user segment consists
of hospitals & clinics and homecare.
The dominant players in the immunoglobulin
market include Grifols SA, Kedrion Biopharma, Sichuan Yuanda
Shuyang Pharmaceutical Co Ltd, Octapharma AG, Kamada Ltd, China Biologic
Products Inc, Shanghai RAAS Blood Products Co Ltd, and LFB Group.
CSL
Behring is a biopharmaceutical company engaged in the manufacturing of plasma-derived
and recombinant therapeutic products. The company’s products are commonly used in
cardiac surgery, organ transplantation, burn treatment, and hemolytic disease
treatment in newborns. BSL Behring has its sales, R&D, and manufacturing
centers globally across various countries. In 2020, the company opened 40 new
plasma collection centers. It uses modern techniques and technologies to
facilitate a highly efficient donation process in its new plasma collection
centers. The company was founded in 1904, and is headquartered in Pennsylvania,
the United States.
Key
deliverables of the report:
· Market CAGR during the forecasting years 2022-2028
· Detailed data highlighting key insights, industry components, and market strategies
· Comprehensive information and estimation of the immunoglobulin market revenue growth in Europe and its influence on the parent market
· In-depth study of forthcoming trends in consumer behavioral patterns
· A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces Model
· A wide-ranging study of factors that will challenge the Europe immunoglobulin
market’s growth during the upcoming years
Want
to get specific insights? Our team of analysts can customize this report based
on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. NORTH
AMERICA IMMUNOGLOBULIN MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
OF COVID-19 ON THE IMMUNOGLOBULIN MARKET
2.2. KEY
INSIGHTS
2.2.1. DEVELOPMENT
OF NEW PURIFICATION METHODS
2.2.2. INCREASING
PREFERENCE FOR PERSONALIZED MEDICINES
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
ATTRACTIVENESS INDEX
2.5. VENDOR
SCORECARD
2.6. KEY
MARKET STRATEGIES
2.6.1. PRODUCT
LAUNCHES & DEVELOPMENTS
2.6.2. PARTNERSHIPS
& AGREEMENTS
2.7. MARKET
DRIVERS
2.7.1. GROWTH
IN THE GERIATRIC POPULATION
2.7.2. PREVALENCE
OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
2.7.3. INCREASING
RESEARCH AND DEVELOPMENT ACTIVITIES
2.8. MARKET
CHALLENGES
2.8.1. HIGH
COST OF THERAPY
2.8.2. HIGH
RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN
2.9. MARKET
OPPORTUNITIES
2.9.1. INCREASING
ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS
2.9.2. GROWING
CLINICAL TRIALS
3. NORTH
AMERICA IMMUNOGLOBULIN MARKET OUTLOOK – BY TYPE
3.1. IGG
3.2. IGA
3.3. IGM
3.4. IGE
3.5. IGD
4. NORTH
AMERICA IMMUNOGLOBULIN MARKET OUTLOOK - BY DELIVERY MODE
4.1. INTRAVENOUS
4.2. SUBCUTANEOUS
4.3. INTRAMUSCULAR
5. NORTH
AMERICA IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION
5.1. HYPOGAMMA
GLOBULINEMIA
5.2. CHRONIC
INFLAMMATORY DEMYELINATING POLYNEUROPATHY
5.3. PRIMARY
IMMUNODEFICIENCY DISEASES
5.4. MYASTHENIA
GRAVIS
5.5. MULTIFOCAL
MOTOR NEUROPATHY
5.6. IDIOPATHIC
THROMBOCYTOPENIC PURPURA (ITP)
5.7. INFLAMMATORY
MYOPATHIES
5.8. SPECIFIC
ANTIBODY DEFICIENCY
5.9. GUILLAIN-BARRE
SYNDROME
5.10. OTHER
APPLICATIONS
6. NORTH
AMERICA IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER
6.1. HOSPITALS
& CLINICS
6.2. HOMECARE
7. NORTH
AMERICA IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL
7.1. HOSPITAL
PHARMACY
7.2. SPECIALTY
PHARMACY
7.3. OTHER
SALES CHANNELS
8. NORTH
AMERICA IMMUNOGLOBULIN MARKET – COUNTRY OUTLOOK
8.1. UNITED
STATES
8.2. CANADA
9. COMPETITIVE
LANDSCAPE
9.1. BIOTEST
AG
9.2. CHINA
BIOLOGIC PRODUCTS INC
9.3. GRIFOLS
SA
9.4. LFB
GROUP
9.5. CSL
BEHRING
9.6. KEDRION
BIOPHARMA
9.7. OCTAPHARMA
AG
9.8. TAKEDA
PHARMACEUTICAL COMPANY LIMITED
9.9. BIO
PRODUCTS LABORATORY
9.10. SHANGHAI
RAAS BLOOD PRODUCTS CO LTD
9.11. PFIZER
INC
9.12. SANQUIN
PLASMA PRODUCTS BV
9.13. ADMA
BIOLOGICS
9.14. SICHUAN
YUANDA SHUYANG PHARMACEUTICAL CO LTD
9.15. KAMADA LTD
10. RESEARCH
METHODOLOGY & SCOPE
10.1. RESEARCH
SCOPE & DELIVERABLES
10.2. SOURCES
OF DATA
10.3. RESEARCH
METHODOLOGY
TABLE 1: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 4: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 5: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 6: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 7: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 8: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
FIGURE 1: MARKET
ATTRACTIVENESS INDEX
FIGURE 2: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)
FIGURE 3: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)
FIGURE 4: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)
FIGURE 5: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)
FIGURE 6: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)
FIGURE 7: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)
FIGURE 8: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)
FIGURE 9: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)
FIGURE 10: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)
FIGURE 11: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)
FIGURE 12: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)
FIGURE 13: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)
FIGURE 14: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY,
2022-2028 (IN $ MILLION)
FIGURE 15: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $
MILLION)
FIGURE 16: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)
FIGURE 17: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)
FIGURE 18: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028
(IN $ MILLION)
FIGURE 19: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)
FIGURE 20: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $
MILLION)
FIGURE 21: NORTH AMERICA IMMUNOGLOBULIN
MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)
FIGURE 22: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)
FIGURE 23: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)
FIGURE 24: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)
FIGURE 25: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)
FIGURE 26: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)
FIGURE 27: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 28: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 29: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)
FIGURE 30: NORTH AMERICA
IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 31: UNITED STATES
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 32: CANADA
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)